ITP Clinical Trial - Gut Microbiota in ITP

Status Recruiting

Clinical Trial Summary

Prospective, observational study to explore the significance of gut microbiome in the diagnosis of ITP, and to identify the predictive value of baseline gut microbiome for GC resistance/relapse.

Clinical Trial Description

A prospective, observational study to (1) collect fecal samples from ITP patients at initial diagnosis (baseline) and after first-line GC treatment, (2) detect the composition of gut microbiome and related metabolites using metagenomic sequencing combined with metabolomics, (3) observe the impact of first-line treatment on gut microbiome, (4) explore the significance of gut microbiome in the diagnosis of ITP, and (5) identify the predictive value of baseline gut microbiome for GC resistance/relapse, thus to provide new ideas for clinical diagnosis and treatment of ITP. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05118126
Study type	Observational
Source	Peking University People's Hospital
Contact	Xiao-Hui Zhang, Dr.
Phone	+8613522338836
Email	zhangxh100@sina.com
Status	Recruiting
Phase
Start date	January 2022
Completion date	December 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05281068` - The Combination of Iguratimod and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia	Phase 2
Recruiting	`NCT05635266` - A Single-Site Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Completed	`NCT02914054` - Therapy of Adults Affected by Idiopathic Thrombocytopenic Purpura With Dexamethasone	Phase 2/Phase 3
Recruiting	`NCT05116423` - Machine-learning Based Prediction Model in Primary Immune Thrombocytopenia
Terminated	`NCT04904276` - Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy
Recruiting	`NCT04747080` - The Combination of Tacrolimus and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia	Phase 2
Not yet recruiting	`NCT04482777` - IL37,Tlymphocytes,NK Cells in Pathogenesis of ITP
Recruiting	`NCT05446831` - Baricitinib for Steroid-resistant/Relapse Immune Thrombocytopenia	Phase 2
Active, not recruiting	`NCT04703621` - The DART Study- Daratumumab Treatment in ITP	Phase 2
Recruiting	`NCT05315778` - Anti-BCMA CAR T-Cell Therapy for R/R ITP	Phase 2
Active, not recruiting	`NCT04943042` - An Observational, Multicenter Study to Evaluate the Use and Effectiveness of Doptelet® in Patients With ITP
Completed	`NCT04089267` - Evaluating the Efficacy and Safety of Different Human Thrombopoietin (rhTPO) Regimens in the Treatment of Patients With Primary Immune Thrombocytopenia (ITP)	Phase 4
Recruiting	`NCT04735588` - Investigation on the Incidence and Course of COVID-19 in Patients With Prior, Ongoing or de Novo ITP. Evaluation of the Impact of COVID-19 Pandemic on the Management of ITP